Donanemab Marketing Authorization: Lilly’s Kisunla for Alzheimer’s

September 25, 2025 Dr. Jennifer Chen Health

Okay, ⁤here’s a formatted list of the references, cleaned up for better readability. I’ve tried to standardize the‌ formatting as much as possible, and included DOIs where available. I’ve⁢ also ⁢noted ​the publication year for each.

References

  1. Alzheimer’s Association. (2023). ‌ 2023 Alzheimer’s disease facts and figures. Alzheimers Dement,19(4),1598-1695.
  2. Wessels AM, Dennehy EB, Dowsett SA, et ⁣al. (2023). Meaningful clinical changes​ in Alzheimer‍ disease measured with the iADRS and illustrated using the donanemab TRAILBLAZER-ALZ study ‌findings. Neurol ⁤Clin Pract, 13(2), e200127. doi:10.1212/CPJ.0000000000200127
  3. Sims Jr, Zimmer Yes, Evans CD, et al. (2023). Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ⁤ 2 Randomized Clinical ​Trial. JAMA,⁣ 330(6), 512-527. doi:10.1001/jama.2023.13239
  4. Ross⁢ EL, Weinberg ​MS, ‍Arnold SE. (2022). Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in ⁢the US. JAMA Neurol, 79(5), 478-487.doi:10.1001/jamaneurol.2022.0315
  5. Boustani M, Doty EG, Garrison LP ⁤Jr, et al. (2022). Assessing the Cost-effectiveness of a‌ Hypothetical Disease-modifying Therapy With ⁢Limited‍ Duration for the Treatment⁤ of Early‌ Symptomatic Alzheimer Disease. Clin Ther, 44(11), 1449-1462. doi:10.1016/j.clinthera.2022.09.008
  6. Mattke S, ⁤Ozawa T, Hanson M. (2023). Implications of Treatment Duration and Intensity on the Value of Alzheimer’s Treatments. Clinical Trials on Alzheimer’s Disease ​(Presented Oct.24-27,2023).
  7. Wang H, Monkul Nery is, Ardyfio P, et⁣ al. (2025).21(4). ⁢doi:10.1002/alz.70062
  8. Gustavsson, A., et al. (2023).Global estimates on ⁤the⁤ number of ⁤persons across the Alzheimer’s disease continuum. Alzheimer’s & Dementia, 19, ⁣658-670. doi:10.1002/alz.12694
  9. alzheimer Europe. (n.d.). Prevalence of​ dementia in Europe. Retrieved from https://www.alzheimer-europe.org/dementia/prevalence-dementia-europe

Notes:

* “n.d.” is used when no date is explicitly provided⁤ for the Alzheimer Europe resource.
* I’ve tried to maintain the original author formatting ​where possible, ‍but some adjustments​ were made ⁣for ‍consistency.
* I’ve removed the‌ tracking links (e.g., edge.prnewswire.com/c/link/?...) as they are not essential for the reference itself.